2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
3
Glioma
2
Diffuse Intrinsic Pontine Glioma
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Liver Cirrhosis
1
Gliosarcoma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Stem Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
163
Carboplatin
146
Paclitaxel
125
Cyclophosphamide
94
130-nm albumin-bound paclitaxel
66
Capecitabine
64
Gemcitabine
54
Doxorubicin
50
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
41
Cisplatin
39
sacituzumab govitecan
34
Nivolumab
34
olaparib
32
Epirubicin
32
Specimen Handling
28
Docetaxel
28
eribulin
27
Bevacizumab
26
durvalumab
25
Drug Therapy
25
Biopsy
24
camrelizumab
23
Magnetic Resonance Spectroscopy
22
toripalimab
19
Radiotherapy
17
spartalizumab
16
Everolimus
15
veliparib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Mebendazole
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn